Role of TIM Family of Molecules in Regulating Transplantation Tolerance
TIM 分子家族在调节移植耐受中的作用
基本信息
- 批准号:8378184
- 负责人:
- 金额:$ 38.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AgonistAlloantigenAllograftingAntibodiesAntigen-Presenting CellsApoptoticBasic ScienceBiochemicalCD4 Positive T LymphocytesCD8B1 geneCell DeathCell SurvivalCellsCessation of lifeChimeric ProteinsEngraftmentEquilibriumFamilyFamily memberGalactose Binding LectinGalectin 3Gene FamilyGoalsGraft RejectionIL2RA geneImmune responseImmunityImmunoglobulinsInfusion proceduresKnowledgeLigandsLigationMitogen-Activated Protein KinasesMolecularMonoclonal AntibodiesMucinsMusNaturePathway AnalysisPathway interactionsPatternPeripheralPhenotypePopulationProteinsReagentRegulationRegulatory T-LymphocyteRoleSignal PathwaySignal TransductionT-Cell ActivationT-LymphocyteTestingTransplantationTransplantation ToleranceWild Type Mouseallograft rejectionallotransplantbasein vivonovelpreventresearch studyresponsetool
项目摘要
We hypothesize that interaction ofT cell Immunoglobulin Mucin (TIM) proteins with their ligands
regulates the aggressive and protective components of the allograft response. Both basic science and
translational aspects are explored. Crucial to our proposal is knowledge that the potential to create
peripheral transplant tolerance is negated in Tim-3 deficient mice and in wild type mice treated with blocking
anti-Tim-3 mAb or Tim-3.Ig fusion proteins. Why? In the absence of the Tim-3-to-galectin-9 interaction, TH1
type alloimmune responses are not properly terminated and the TREG compartment does not expand. New
experiments reveal that Tim-3 is expressed on CD4+ TH17 and CD8+ CTLs (Tc1) effector T cells as well as
terminally differentiated TH1 cells. These findings serve to magnify the importance of the Tim-3-to-galectin-9
interaction in the effector T cell allograft response. Another Tim family member Tim-1 is expressed on all
activated T cells and we have identified Tim-4 that is expressed on antigen presenting cells as the ligand for
Tim-1. We have now identified antagonist .type anti-Tim-1 mAbs as well as agonist type anti-Tim-1 mAbs.
The 3B3 agonist mAb and Tim-4.Ig, act as potent T cell co stimulants. In vivo administration of the agonist
mAb blocks the induction of transplant tolerance by co stimulation blockade, favors polarization of the
allograft response into a TH"!/ Tn17 pattern while inhibiting expansion/function of TregS. In contrast, infusion of
an antagonist type anti-Tim-1 mAb (RMT 1-10) aids tolerance induction and polarizes the allograft response
into a TH2/ Treg dominant mode. Using these novel tools we propose to explore the role of Tim family of
molecules in the regulation of transplantation tolerance. Specifically, we hypothesize that the (i) Tim-3-togalectin-
9 interaction gates the cytopathic alloreactive TH1, Tc1 as well as the newly recognized TH17
compartments and reciprocally regulates the donor reactive TREc compartment, and (ii) Tim-1 -to-Tim-4
interaction regulates the intensity and direction of CD4+ T cell activation. The specific aims are to analyze:
1) the Tim-3-galectin 9 axis in the allograft response; 2) the Tim1-Tim-4 axis in the allograft response; and
3) T cell signaling pathways in the context of Tim-1 and Tim-3 engagement. These studies will provide a
functional and mechanistic understanding of how Tim-1 and Tim-3 molecules upon interaction with their
ligand regulate immune responses to allotransplants.
我们假设这种相互作用oft细胞免疫球蛋白粘蛋白(TIM)蛋白与配体
调节同种异体移植反应的侵略性和保护性成分。基础科学和
探索了翻译方面。对我们的建议至关重要的是,知道创造的潜力
在TIM-3缺乏小鼠和用阻塞治疗的野生型小鼠中,外围移植耐受性被否定
抗TIM-3 mAb或tim-3.ig融合蛋白。为什么?在没有TIM-3到Galectin-9相互作用的情况下,Th1
类型AlloMune响应未正确终止,Treg隔室没有扩展。新的
实验表明,TIM-3在CD4+ TH17和CD8+ CTL(TC1)效应T细胞以及
末端分化的Th1细胞。这些发现有助于放大TIM-3至galectin-9的重要性
效应T细胞同种异体移植反应中的相互作用。蒂姆家族成员蒂姆1对所有人表示
活化的T细胞,我们已经确定了在抗原呈递细胞上表达的TIM-4作为配体
Tim-1。现在,我们已经鉴定出拮抗剂.Type抗TIM-1 MAB以及激动剂型抗TIM-1 MAB。
3B3激动剂mAb和tim4.ig充当有效的T细胞CO刺激剂。激动剂的体内给药
mAb通过CO刺激阻断阻塞移植耐受性的诱导,有利于偏振
同种异体移植反应对TH“!/ TN17模式,同时抑制Tregs的扩张/功能。相反,输注
拮抗剂型抗TIM-1 MAB(RMT 1-10)有助于耐受性诱导并极化同种异体移植反应
进入TH2/ Treg主导模式。我们建议使用这些新颖的工具来探索蒂姆家族的作用
分子调节移植耐受性。具体而言,我们假设(i)tim-3-----------------------
9相互作用的细胞疗法同种异体反应性TH1,TC1以及新认可的TH17
隔室和相互调节的供体反应性TREC室,(ii)TIM-1-1至TIM-4
相互作用调节CD4+ T细胞活化的强度和方向。具体目的是分析:
1)同种异体移植反应中的TIM-3-甘氏蛋白9轴; 2)同种异体移植反应中的TIM1-TIM-4轴;和
3)TIM-1和TIM-3参与度的T细胞信号通路。这些研究将提供
对TIM-1和TIM-3分子与其相互作用时如何进行功能和机械理解
配体调节对同种异体植物的免疫反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TERRY B. STROM其他文献
TERRY B. STROM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TERRY B. STROM', 18)}}的其他基金
Inflammation and the Balance of Cytopathic versus Regulatory T Cells
炎症以及细胞病变与调节性 T 细胞的平衡
- 批准号:
7644028 - 财政年份:2008
- 资助金额:
$ 38.83万 - 项目类别:
Inflammation and T Cell Memory: Inter-related Barriers to Allograft Tolerance
炎症和 T 细胞记忆:同种异体移植耐受的相互关联的障碍
- 批准号:
7487996 - 财政年份:2007
- 资助金额:
$ 38.83万 - 项目类别:
Inflammation and T Cell Memory: Inter-related Barriers to Allograft Tolerance
炎症和 T 细胞记忆:同种异体移植耐受的相互关联的障碍
- 批准号:
7928084 - 财政年份:2007
- 资助金额:
$ 38.83万 - 项目类别:
Inflammation and T Cell Memory: Inter-related Barriers to Allograft Tolerance
炎症和 T 细胞记忆:同种异体移植耐受的相互关联的障碍
- 批准号:
7293367 - 财政年份:2007
- 资助金额:
$ 38.83万 - 项目类别:
Inflammation and T Cell Memory: Inter-related Barriers to Allograft Tolerance
炎症和 T 细胞记忆:同种异体移植耐受的相互关联的障碍
- 批准号:
8117651 - 财政年份:2007
- 资助金额:
$ 38.83万 - 项目类别:
Inflammation and the Balance of Cytopathic versus Regulatory T Cells
炎症以及细胞病变与调节性 T 细胞的平衡
- 批准号:
7338986 - 财政年份:2007
- 资助金额:
$ 38.83万 - 项目类别:
Inflammation and T Cell Memory: Inter-related Barriers to Allograft Tolerance
炎症和 T 细胞记忆:同种异体移植耐受的相互关联的障碍
- 批准号:
7684588 - 财政年份:2007
- 资助金额:
$ 38.83万 - 项目类别:
Novel Approaches To Achieve Allograft Tolerance
实现同种异体移植耐受的新方法
- 批准号:
6532898 - 财政年份:2001
- 资助金额:
$ 38.83万 - 项目类别:
相似国自然基金
菌根真菌介导的同种密度制约对亚热带森林群落物种共存的影响
- 批准号:32371600
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
B7H4-LILRB4信号调控B细胞代谢重编程机制在同种抗体产生及防治AMR中的作用
- 批准号:82371792
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
利用HERV-K(HML-2)多态性探讨不同种族群体的遗传多样性和疾病易感性差异
- 批准号:32200491
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
抗骨髓瘤的新型同种异体嵌合抗原受体T(CAR T)细胞疗法研发
- 批准号:82270210
- 批准年份:2022
- 资助金额:68 万元
- 项目类别:面上项目
利用HERV-K(HML-2)多态性探讨不同种族群体的遗传多样性和疾病易感性差异
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Peptide-dependent mobilization of CD8 regulatory cells in cardiac transplantation
心脏移植中 CD8 调节细胞的肽依赖性动员
- 批准号:
10585628 - 财政年份:2023
- 资助金额:
$ 38.83万 - 项目类别:
Sphingosine 1 phosphate receptors 1 and 3 as novel targets in transplantation
鞘氨醇 1 磷酸受体 1 和 3 作为移植新靶点
- 批准号:
8432025 - 财政年份:2012
- 资助金额:
$ 38.83万 - 项目类别:
Sphingosine 1 phosphate receptors 1 and 3 as novel targets in transplantation
鞘氨醇 1 磷酸受体 1 和 3 作为移植新靶点
- 批准号:
8803791 - 财政年份:2012
- 资助金额:
$ 38.83万 - 项目类别:
Sphingosine 1 phosphate receptors 1 and 3 as novel targets in transplantation
鞘氨醇 1 磷酸受体 1 和 3 作为移植新靶点
- 批准号:
8604390 - 财政年份:2012
- 资助金额:
$ 38.83万 - 项目类别:
Sphingosine 1 phosphate receptors 1 and 3 as novel targets in transplantation
鞘氨醇 1 磷酸受体 1 和 3 作为移植新靶点
- 批准号:
9000694 - 财政年份:2012
- 资助金额:
$ 38.83万 - 项目类别: